Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents

Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3

Abstract

AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor currently is under evaluation in phase 1 and 2 clinical trials and has demonstrated activity in both hematologic and solid tumor malignancies. This report focuses on the preclinical characterization of the pharmacokinetics of AR-42 in mice and rats. A high-performance liquid chromatography–tandem mass spectrometry assay has been developed and applied to the pharmacokinetic study of the more active stereoisomer, S-AR-42, when administered via intravenous and oral routes in rodents, including plasma, bone marrow, and spleen pharmacokinetics (PK) in CD2F1 mice and plasma PK in F344 rats. Oral bioavailability was estimated to be 26 and 100% in mice and rats, respectively. R-AR-42 was also evaluated intravenously in rats and was shown to display different pharmacokinetics with a much shorter terminal half-life compared to that of S-AR-42. Renal clearance was a minor elimination pathway for parental S-AR-42. Oral administration of S-AR-42 to tumor-bearing mice demonstrated high uptake and exposure of the parent drug in the lymphoid tissues, spleen, and bone marrow. This is the first report of the pharmacokinetics of this novel agent, which is now in early phase clinical trials.

Authors and Affiliations

Hao Cheng, Zhiliang Xie, William P. Jones, Xiaohui Tracey Wei, Zhongfa Liu, Dasheng Wang, Samuel K. Kulp, Jiang Wang, Christopher C. Coss, Ching-Shih Chen, Guido Marcucci, Ramiro Garzon, Joseph M. Covey, Mitch A. Phelps, Kenneth K. Chan

Keywords

Related Articles

Direct pelletization in a rotary processor controlled by torque measurements. II: Effects of changes in the content of microcrystalline cellulose

In the present study we investigated the effect of changes in the content of microcrystalline cellulose (MCC) on a direct pelletization process in a rotary processor in which the liquid addition was terminated once a cer...

Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT

The online version of this article (doi:10.1208/s12248-011-9257-x) contains supplementary material, which is available to authorized users.

Oral bioavailability in pigs of a miconazole/Hydroxypropyl-γ-cyclodextrin/ L-tataric acid inclusion complex produced by supercritical carbon dioxide processing

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-γ-cyclodextrin(HPγCD)/ L-tartaric acid inclusion complex p...

Therapeutic Applications of Curcumin Nanoformulations

Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseas...

Download PDF file
  • EP ID EP680881
  • DOI  10.1208/s12248-016-9876-3
  • Views 37
  • Downloads 0

How To Cite

Hao Cheng, Zhiliang Xie, William P. Jones, Xiaohui Tracey Wei, Zhongfa Liu, Dasheng Wang, Samuel K. Kulp, Jiang Wang, Christopher C. Coss, Ching-Shih Chen, Guido Marcucci, Ramiro Garzon, Joseph M. Covey, Mitch A. Phelps, Kenneth K. Chan (2016). Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. The AAPS Journal, 18(3), -. https://europub.co.uk/articles/-A-680881